213 related articles for article (PubMed ID: 36618924)
1. Genetically proxied inhibition of tumor necrosis factor and the risk of colorectal cancer: A drug-target mendelian randomization study.
Chen M; Chen Q; Xiao XY; Feng SJ; Wang XY; Tang TC; Zheng H
Front Pharmacol; 2022; 13():1079953. PubMed ID: 36618924
[No Abstract] [Full Text] [Related]
2. Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study.
Kang X; Ploner A; Pedersen NL; Bandres-Ciga S; Noyce AJ; Wirdefeldt K; Williams DM
Neurology; 2021 Mar; 96(12):e1672-e1679. PubMed ID: 33608417
[TBL] [Abstract][Full Text] [Related]
3. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.
Yarmolinsky J; Díez-Obrero V; Richardson TG; Pigeyre M; Sjaarda J; Paré G; Walker VM; Vincent EE; Tan VY; Obón-Santacana M; Albanes D; Hampe J; Gsur A; Hampel H; Pai RK; Jenkins M; Gallinger S; Casey G; Zheng W; Amos CI; ; ; ; Smith GD; Martin RM; Moreno V
PLoS Med; 2022 Feb; 19(2):e1003897. PubMed ID: 35113855
[TBL] [Abstract][Full Text] [Related]
4. TNF inhibitors associated with cardiovascular diseases and cardiometabolic risk factors: a Mendelian randomization study.
Liu ZY; Huang XB; Yang GM; Zhao S
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(18):8556-8578. PubMed ID: 37782172
[TBL] [Abstract][Full Text] [Related]
5. Mendelian randomization study on the causal effects of tumor necrosis factor inhibition on coronary artery disease and ischemic stroke among the general population.
Kang X; Jiao T; Wang H; Pernow J; Wirdefeldt K
EBioMedicine; 2022 Feb; 76():103824. PubMed ID: 35074627
[TBL] [Abstract][Full Text] [Related]
6. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study.
Morales Berstein F; McCartney DL; Lu AT; Tsilidis KK; Bouras E; Haycock P; Burrows K; Phipps AI; Buchanan DD; Cheng I; ; Martin RM; Davey Smith G; Relton CL; Horvath S; Marioni RE; Richardson TG; Richmond RC
Elife; 2022 Mar; 11():. PubMed ID: 35346416
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor necrosis factor receptor 1 and the risk of periodontitis.
Alayash Z; Baumeister SE; Holtfreter B; Kocher T; Baurecht H; Ehmke B; Reckelkamm SL; Nolde M
Front Immunol; 2023; 14():1094175. PubMed ID: 36845132
[TBL] [Abstract][Full Text] [Related]
8. Mendelian randomization study of inflammatory bowel disease and bone mineral density.
Wu F; Huang Y; Hu J; Shao Z
BMC Med; 2020 Nov; 18(1):312. PubMed ID: 33167994
[TBL] [Abstract][Full Text] [Related]
9. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
10. Effects of ulcerative colitis and Crohn's disease on neurodegenerative diseases: A Mendelian randomization study.
Li H; Wen Z
Front Genet; 2022; 13():846005. PubMed ID: 36046231
[No Abstract] [Full Text] [Related]
11. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
12. Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study.
Liu L; Sheng C; Lyu Z; Dai H; Chen K
Front Nutr; 2021; 8():755834. PubMed ID: 34712689
[TBL] [Abstract][Full Text] [Related]
13. The effect of immunomodulatory drugs on aortic stenosis: a Mendelian randomisation analysis.
Ciofani JL; Han D; Nazarzadeh M; Allahwala UK; De Maria GL; Banning AP; Bhindi R; Rahimi K
Sci Rep; 2023 Nov; 13(1):18810. PubMed ID: 37914784
[TBL] [Abstract][Full Text] [Related]
14. Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study.
Cui G; Li S; Ye H; Yang Y; Huang Q; Chu Y; Shi Z; Zhang X
Front Immunol; 2022; 13():956005. PubMed ID: 36159838
[TBL] [Abstract][Full Text] [Related]
15. Effect of C-reactive protein on the risk of Heart failure: a mendelian randomization study.
Habibi D; Daneshpour MS; Asgarian S; Kohansal K; Hadaegh F; Mansourian M; Akbarzadeh M
BMC Cardiovasc Disord; 2023 Mar; 23(1):112. PubMed ID: 36882679
[TBL] [Abstract][Full Text] [Related]
16. Blood Lipids and the Risk of Colorectal Cancer: Mendelian Randomization Analyses in the Japanese Consortium of Genetic Epidemiology Studies.
Iwagami M; Goto A; Katagiri R; Sutoh Y; Koyanagi YN; Nakatochi M; Nakano S; Hanyuda A; Narita A; Shimizu A; Tanno K; Hozawa A; Kinoshita K; Oze I; Ito H; Yamaji T; Sawada N; Nakamura Y; Nakamura S; Kuriki K; Suzuki S; Hishida A; Kasugai Y; Imoto I; Suzuki M; Momozawa Y; Takeuchi K; Yamamoto M; Sasaki M; Matsuo K; Tsugane S; Wakai K; Iwasaki M
Cancer Prev Res (Phila); 2022 Dec; 15(12):827-836. PubMed ID: 36040498
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory markers and the risk of idiopathic sudden sensorineural hearing loss: A Mendelian randomization study.
Zhou T; Chen M; Yuan Z; Xia Z; Zhang S; Zhang Z; Chen H; Lin R
Front Neurol; 2023; 14():1111255. PubMed ID: 36908593
[TBL] [Abstract][Full Text] [Related]
18. Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study.
Bell AS; Rosoff DB; Mavromatis LA; Jung J; Wagner J; Lohoff FW
J Am Heart Assoc; 2022 Nov; 11(21):e026122. PubMed ID: 36285785
[TBL] [Abstract][Full Text] [Related]
19. Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study.
Prins BP; Abbasi A; Wong A; Vaez A; Nolte I; Franceschini N; Stuart PE; Guterriez Achury J; Mistry V; Bradfield JP; Valdes AM; Bras J; Shatunov A; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Lu C; Han B; Raychaudhuri S; Bevan S; Mayes MD; Tsoi LC; Evangelou E; Nair RP; Grant SF; Polychronakos C; Radstake TR; van Heel DA; Dunstan ML; Wood NW; Al-Chalabi A; Dehghan A; Hakonarson H; Markus HS; Elder JT; Knight J; Arking DE; Spector TD; Koeleman BP; van Duijn CM; Martin J; Morris AP; Weersma RK; Wijmenga C; Munroe PB; Perry JR; Pouget JG; Jamshidi Y; Snieder H; Alizadeh BZ
PLoS Med; 2016 Jun; 13(6):e1001976. PubMed ID: 27327646
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study.
Nolde M; Alayash Z; Reckelkamm SL; Kocher T; Ehmke B; Holtfreter B; Baurecht H; Georgakis MK; Baumeister SE
Front Immunol; 2023; 14():1160148. PubMed ID: 37342352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
